We have collaboration with leading biotech and pharmaceutical companies, as well as top-tier academic institutions and hospitals. These partnerships highlight the depth of our scientific expertise and the strength of our research and development leadership in the cell therapy field.
GC Cell is a leading Korean biotechnology company focused on immune cell therapies, including CAR-NK, CAR-T, and CIK cell platforms, and CDMO services for cell and gene therapy. IASO Bio and GC Cell entered into an exclusive license agreement to bring the CAR-T therapy Fucaso (Equecabtagene Autoleucel) to the South Korean market for the treatment of multiple myeloma.
Umoja Biopharma, Inc.is an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies. IASO Bio and Umoja Biopharma entered into a research collaboration to bring off-the-Shelf therapies to patients with hematological malignancies.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases. IASO Bio and Cabaletta Bio entered into an exclusive worldwide license agreement for clinically validated CD19 binder.
Innovent Biologics has a strong track record in research and development of high-end biomedicines, clinical studies and product launch. IASO partnered with Innovent in the joint development of a BCMA-targeted CAR-T cell therapy.
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines.IASO Bio,Innovent and Sana have entered into an agreement pursuant for clinical validated BCMA CAR construct.
Tongji Hospital (TJH) is one of the leading hospitals specializing in cell therapies. IASO and TJH have jointly conducted IIT and registrational clinical studies on multiple cell therapies.
